Hepatic enhancement of Gd-EOB-DTPA-enhanced 3 Tesla MR imaging: Assessing severity of liver cirrhosis

Abstract

Purpose: To evaluate the usefulness of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging in assessing the severity of cirrhosis and liver function. Materials and Methods: This retrospective study included 120 patients who underwent Gd-EOB-DTPA-enhanced 3 Tesla (T) MR imaging (normal liver, n = 30; Child-Pugh class A, n = 30; B, n = 30; and C, n = 30). Groups were matched for underlying disease, age (±5 years), gender, and creatinine (±0.05 mg/dL). Contrast enhancement index (CEI) was calculated and compared between normal and cirrhosis groups. We analyzed the correlation between hepatic function parameters and CEI at hepatobiliary phase (HP). Results: The degree and time course of hepatic enhancement significantly differed between normal and each cirrhosis group (P < 0.001). Mean CEI at HP constantly and significantly decreased as the severity of cirrhosis increased (P < 0.001). Total bilirubin (P = 0.022), albumin (P < 0.001), platelet count (P = 0.04), and Model for End Stage Liver Disease score (P = 0.01) were independent predictors of hepatic enhancement at HP. Conclusion: The degree of hepatic enhancement on Gd-EOB-DTPA indicates the severity of cirrhosis and is correlated with hepatic function parameters. J. Magn. Reson. Imaging 2016;44:1339–1345.